Cypherpunk unit Leap publishes Phase 2 DeFianCe data on sirexatamab in second-line metastatic colorectal cancer - CYPH News | RalliesCypherpunk unit Leap publishes Phase 2 DeFianCe data on sirexatamab in second-line metastatic colorectal cancer
C
CYPH• Phase 2 DeFianCe results published in peer-reviewed journal
- Cypherpunk Technologies reported peer-reviewed publication of Phase 2 DeFianCe trial results for sirexatamab in second-line metastatic colorectal cancer.
- Results were presented in the new journal publication, not as a future conference readout.
- Overall study readout was mixed, with the main population falling short of the trial’s primary goal.
- Benefit appeared concentrated in patients with higher baseline plasma DKK1, supporting a biomarker-selected Phase 3 strategy.
- Safety profile broadly matched standard therapy, with no meaningful new tolerability signal from adding sirexatamab.
